Malignant Pleural Effusion Market
Malignant Pleural Effusion Market infographics

Malignant Pleural Effusion

A Malignant Pleural Effusion (MPE) is the build-up of fluid and cancer cells that collects between the chest wall and the lung. This can cause shortness of breath and/or chest discomfort. It is a fairly common complication in several different cancers. It forms when cells from either lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid.


Malignant Pleural Effusion Epidemiology Segmentation in the 7MM


  • Total Incident Cases of Pleural Effusion
  • Total Incident Cases of Malignant Pleural Effusion
  • Total Diagnosed Cases of Malignant Pleural Effusion
  • Total Incident Cases of Malignant Pleural Effusion by Tumor Type
  • Total Treated Cases of Malignant Pleural Effusion


Malignant Pleural Effusion Epidemiological Insights Observed in the 7MM (2021)


  • The total number of incident cases of Malignant Pleural Effusion observed in the 7MM was observed to be 640K in the year 2021
  • The highest diagnosed Malignant Pleural Effusion population accounting for 542K cases, was found in the United States, followed by EU5 (306K) and Japan (123K) in the year 2021. 


Malignant Pleural Effusion Market Insight


  • The market size of Malignant Pleural Effusion in the 7MM was found to be approximately USD 4,561 million in 2021
  • The market size of Malignant Pleural Effusion in the United States was found to be approximately USD 1,174 million in 2021
  • The market size of Malignant Pleural Effusion in the EU5 was found to be approximately USD 1,772 million in 2021
  • The market size of Malignant Pleural Effusion in the Japan was found to be approximately USD 1,076 million in 2021


Malignant Pleural Effusion Market Strengths

The rising number of various tumor cases (heart, lungs, and breast) is the primary strength of the global market for malignant pleural effusion.


Malignant Pleural Effusion Market Opportunities

The newer drug regimens have been shown to improve the patient's overall survival, which can benefit patients in terms of maintaining the QoL and delaying neurological deterioration.


Malignant Pleural Effusion Emerging Drugs and Key Companies


  • RSO-021: RS Oncology
  • GL-ONC1: Genelux Corporation
  • CAN-2409: Candel Therapeutics, and ot7hers